Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Non-Current Assets (2016 - 2025)

Agios Pharmaceuticals' Other Non-Current Assets history spans 14 years, with the latest figure at $3.9 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 16.79% year-over-year to $3.9 million; the TTM value through Dec 2025 reached $3.9 million, down 16.79%, while the annual FY2025 figure was $3.9 million, 16.79% down from the prior year.
  • Other Non-Current Assets reached $3.9 million in Q4 2025 per AGIO's latest filing, roughly flat from $3.9 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $53.4 million in Q1 2021 to a low of $2.9 million in Q4 2021.
  • Average Other Non-Current Assets over 5 years is $6.7 million, with a median of $4.0 million recorded in 2022.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 2866.22% in 2021, then crashed 94.57% in 2022.
  • A 5-year view of Other Non-Current Assets shows it stood at $2.9 million in 2021, then surged by 36.41% to $4.0 million in 2022, then grew by 2.55% to $4.1 million in 2023, then rose by 16.44% to $4.7 million in 2024, then decreased by 16.79% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Other Non-Current Assets are $3.9 million (Q4 2025), $3.9 million (Q3 2025), and $3.9 million (Q2 2025).